Brokerages Set Evolus, Inc. (NASDAQ:EOLS) Price Target at $16.00

Evolus, Inc. (NASDAQ:EOLS) has received a consensus recommendation of “Moderate Buy” from the six research firms that are covering the firm, MarketBeat reports. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating on the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $16.00.

A number of brokerages have recently issued reports on EOLS. Needham & Company LLC reiterated a “hold” rating on shares of Evolus in a report on Wednesday, December 24th. Stifel Nicolaus reduced their target price on Evolus from $20.00 to $17.00 and set a “buy” rating for the company in a research note on Tuesday, January 13th. HC Wainwright dropped their price objective on shares of Evolus from $20.00 to $13.00 and set a “buy” rating on the stock in a report on Tuesday, February 3rd. BTIG Research restated a “buy” rating and issued a $13.00 price objective on shares of Evolus in a research report on Wednesday, March 4th. Finally, Weiss Ratings restated a “sell (e+)” rating on shares of Evolus in a research report on Monday, December 22nd.

Insider Transactions at Evolus

In other news, insider David Moatazedi sold 13,669 shares of the company’s stock in a transaction on Friday, March 20th. The stock was sold at an average price of $4.75, for a total value of $64,927.75. Following the transaction, the insider owned 604,700 shares of the company’s stock, valued at $2,872,325. This represents a 2.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider Rui Avelar sold 29,996 shares of the company’s stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $4.89, for a total transaction of $146,680.44. Following the completion of the transaction, the insider owned 430,542 shares in the company, valued at approximately $2,105,350.38. This represents a 6.51% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 163,504 shares of company stock valued at $797,184. 5.90% of the stock is owned by insiders.

Institutional Investors Weigh In On Evolus

Several large investors have recently added to or reduced their stakes in the business. Manchester Capital Management LLC purchased a new position in Evolus in the second quarter worth approximately $26,000. State of Alaska Department of Revenue acquired a new stake in shares of Evolus during the third quarter worth about $26,000. Larson Financial Group LLC grew its position in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock worth $33,000 after acquiring an additional 2,837 shares during the last quarter. Meeder Asset Management Inc. purchased a new position in Evolus during the 4th quarter worth $34,000. Finally, Wexford Capital LP purchased a new stake in shares of Evolus during the third quarter worth approximately $37,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Evolus Stock Performance

Shares of NASDAQ:EOLS opened at $4.03 on Friday. Evolus has a one year low of $3.86 and a one year high of $12.28. The firm has a market cap of $262.19 million, a PE ratio of -4.98 and a beta of 1.00. The firm’s 50 day simple moving average is $4.61 and its 200-day simple moving average is $5.85.

Evolus (NASDAQ:EOLS) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported $0.00 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.09). The firm had revenue of $90.30 million during the quarter, compared to analyst estimates of $89.58 million. Equities research analysts predict that Evolus will post -0.61 EPS for the current fiscal year.

About Evolus

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.